Liraglutide for Prediabetes: Evidence, Eligibility, Coverage

Liraglutide is not FDA approved for prediabetes. It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In SCALE Obesity and Prediabetes, people on Saxenda lost 7.4% of body weight on average, vs 3% on placebo.

Brands: Victoza and Saxenda
Best result (SCALE Obesity and Prediabetes): 7.4% weight loss

A quick look at Saxenda

How long the drug stays in your body

About 13 hours is the half-life. After 13 h, half is gone; about 3% remains at five half-lives (2.7 d).

Weight loss in the main study

In the SCALE Obesity and Prediabetes, 56 weeks trial, weight loss was 7.4% of body weight, compared with 3% on placebo.

See the FDA DailyMed label.

Who qualifies?

Who qualifies for liraglutide
Who sets the rule	Who qualifies
Victoza	For people 10 and older with type 2 diabetes, it lowers blood sugar alongside diet and exercise.
Victoza	For adults with type 2 diabetes and heart disease, it lowers the chance of a heart attack, stroke, or death tied to the heart.
Saxenda	Diet and activity go with weight loss and maintaining it long term. This applies to adults and children aged 12 or older (over 60 kg) with obesity, and to adults with overweight plus a weight-related condition.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	the first step is a 6-month diet and activity program

Sources include the DailyMed FDA label, 1 and 2, plus aetna.com

Results of the Prediabetes trial

The trials included more than just people with prediabetes. Every participant was an adult with obesity or overweight, and none had type 2 diabetes.

Liraglutide trials in prediabetes
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SCALE Obesity and Prediabetes	Saxenda	All were adults with obesity or overweight, and none had type 2 diabetes	56 weeks	3,731	7.4% weight loss	3% on placebo

Trial source: SCALE Obesity and Prediabetes (FDA label (DailyMed)).

What is different with prediabetes?

Points from the Liraglutide prediabetes label
What changes	What the label says	Labels
Hypoglycemia	When taken with insulin or a sulfonylurea, it raises the risk of low blood sugar, so those doses may need to be lower.	All of them
Taken with insulin or sulfonylureas	Low blood sugar is more likely when you combine it with insulin or sulfonylureas such as glipizide or glimepiride, and your doctor may lower those doses.	All of them

From these FDA labels: FDA DailyMed label.

Label warnings: FDA DailyMed label.

Coverage for prediabetes

A GLP-1 used only for weight loss is not covered by Medicare Part D.

When Medicaid covers weight-loss GLP-1s, prior authorization is standard.

Sources: humana.com, KFF.

Alternatives for prediabetes

GLP-1 medicines and prediabetes
Medicine	For prediabetes	How it is taken	Trial result
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed